Patents Assigned to Universitat Graz
-
Patent number: 9279129Abstract: A mutant Pichia pastoris alcohol oxidase 1 (AOX1) promoter of the wild type Pichia pastoris AOX1 promoter (SEQ ID No. 1) comprising at least one mutation selected from the group consisting of: a) a transcription factor binding site (TFBS), b) nucleotides 170 to 235 (?784 to ?719), nucleotides 170 to 191 (?784 to ?763), nucleotides 192 to 213 (?762 to ?741), nucleotides 192 to 210 (?762 to ?744), nucleotides 207 to 209 (?747 to ?745), nucleotides 214 to 235 (?740 to ?719), nucleotides 304 to 350 (?650 to ?604), nucleotides 364 to 393 (?590 to ?561), nucleotides 434 to 508 (?520 to ?446), nucleotides 509 to 551 (?445 to ?403), nucleotides 552 to 560 (?402 to ?394), nucleotides 585 to 617 (?369 to ?337), nucleotides 621 to 660 (?333 to ?294), nucleotides 625 to 683 (?329 to ?271), nucleotides 736 to 741 (?218 to ?213), nucleotides 737 to 738 (?217 to ?216), nucleotides 726 to 755 (?228 to ?199), nucleotides 784 to 800 (?170 to ?154) or nucleotides 823 to 861 (?131 to ?93) of Seq ID No.Type: GrantFiled: April 14, 2010Date of Patent: March 8, 2016Assignees: TECHNISCHE UNIVERSITAT GRAZ, VTU HOLDING GMBHInventors: Franz Hartner, Anton Glieder
-
Patent number: 9273291Abstract: The invention relates to an enzyme that comprises or includes a sequence according to SEQ. ID No. 1 or SEQ. ID No. 2, to a method for the production thereof, and to the use thereof as a catalyst in the oxidative cleavage of vinyl aromatics.Type: GrantFiled: August 9, 2012Date of Patent: March 1, 2016Assignee: Universitat GrazInventors: Aashrita Rajagopalan, Wolfgang Kroutil, Markus Schober
-
Patent number: 9206115Abstract: A compound of formula (I) as defined herein is useful in the treatment and prevention of a disorder such as cachexia, stroke, atherosclerosis, coronary artery disease, and diabetes and pharmaceutical compositions of the same. Also, a method of screening for lipase inhibitors using a compound of formula (I) and determining its lipase inhibitory activity. The method includes in vitro assays of compounds using ATGL and/or HSL, and cellular assays wherein inhibition is followed by observing indicators of efficacy. Also, methods for treatment or prevention of a condition involving cachexia, stroke, artherosclerosis, coronary artery disease, diabetes, preferably diabetes type II by administering a pharmaceutical composition comprising an agent which is able to inhibit ATGL. Also contemplated herein, are compositions comprising one or more ATGL-inhibiting agents optionally in combination with one or more lipase inhibitors or inhibitors of inflammatory cytokines.Type: GrantFiled: January 23, 2014Date of Patent: December 8, 2015Assignees: Technische Universität Graz, Karl-Franzens-Universität GrazInventors: Martina Schweiger, Matthias Romauch, Robert Zimmermann, Nicole Mayer, Rolf Breinbauer
-
Patent number: 9161014Abstract: Method for compensating illumination deficiencies in microscopic “shape from focus (SFF)”, wherein firstly the reflectance of the scene is estimated by way of a projector-camera system and then microscopic “shape from focus (SFF)” is applied to a stack of reflectance maps rather than to the original image data.Type: GrantFiled: July 26, 2011Date of Patent: October 13, 2015Assignees: Alicona Imaging GmbH, Technische Universität GrazInventors: Manfred Prantl, Stefan Scherer, Martin Lenz, Matthias Ruther, Horst Bischof
-
Patent number: 9012175Abstract: A mutant Pichia pastoris alcohol oxidase 1 (AOX1) promoter of the wild type Pichia pastoris AOX1 promoter (SEQ ID No. 1) comprising at least one mutation selected from the group consisting of: a) a transcription factor binding site (TFBS), b) nucleotides 170 to 235 (?784 to ?719), nucleotides 170 to 191 (?784 to ?763), nucleotides 192 to 213 (?762 to ?741), nucleotides 192 to 210 (?762 to ?744), nucleotides 207 to 209 (?747 to ?745), nucleotides 214 to 235 (?740 to ?719), nucleotides 304 to 350 (?650 to ?604), nucleotides 364 to 393 (?590 to ?561), nucleotides 434 to 508 (?520 to ?446), nucleotides 509 to 551 (?445 to ?403), nucleotides 552 to 560 (?402 to ?394), nucleotides 585 to 617 (?369 to ?337), nucleotides 621 to 660 (?333 to ?294), nucleotides 625 to 683 (?329 to ?271), nucleotides 736 to 741 (?218 to ?213), nucleotides 737 to 738 (?217 to ?216), nucleotides 726 to 755 (?228 to ?199), nucleotides 784 to 800 (?170 to ?154) or nucleotides 823 to 861 (?131 to ?93) of Seq ID No.Type: GrantFiled: February 23, 2006Date of Patent: April 21, 2015Assignees: Technische Universitat Graz, VTU Holding GmbHInventors: Franz Hartner, Anton Glieder
-
Patent number: 8981024Abstract: The present invention relates to pre-catalysts for olefin metathesis and composition involving these pre-catalysts.Type: GrantFiled: September 3, 2012Date of Patent: March 17, 2015Assignee: Technische Universität GrazInventors: Christian Slugovc, Julia Wappel
-
Publication number: 20150064756Abstract: The invention relates to an enzyme that comprises or includes a sequence according to SEQ. ID No. 1 or SEQ. ID No. 2, to a method for the production thereof, and to the use thereof as a catalyst in the oxidative cleavage of vinyl aromatics.Type: ApplicationFiled: August 9, 2012Publication date: March 5, 2015Applicant: UNIVERSITAT GRAZInventors: Aashrita Rajagopalan, Wolfgang Kroutil, Markus Schober
-
Patent number: 8962008Abstract: The present invention relates to a novel polymeric material with enhanced hydrophilicity for medical use comprising a biocompatible polyester material selected from the group consisting of poly(hydroxyalkanoate)s, poly(lactic acid)s, poly(glycolic acid)s, poly(caprolactone)s and copolymers and blends thereof, wherein the biocompatible polyester material is crosslinked with a functionalized poly(alkylene oxide) having at least two functional groups independently selected from the group consisting of azido-formate and alkanoyl azide. The novel polymeric material with enhanced hydrophilicity is useful as a biocompatible material in a variety of medical applications, including medical implants, bioresorbable implants, tissue engineering, and controlled release.Type: GrantFiled: June 20, 2012Date of Patent: February 24, 2015Assignees: Technische Universitat Graz, Medical University of Graz MUG, AT&S Austria Technologie & Systemtechnik Aktiengesellschaft, Herabus Medical GmbHInventors: Frank Wiesbrock, Clemens Ebner, Franz Stelzer, Annelie-Martina Weinberg, Klaus-Dieter Kühn
-
Patent number: 8951995Abstract: The present invention relates to the use of nor-ursodeoxycholic acid for the manufacture of a drug for the treatment and/or the prevention of liver diseases, preferably chronic liver diseases.Type: GrantFiled: May 12, 2005Date of Patent: February 10, 2015Assignee: Medizinische Universitat GrazInventors: Michael Trauner, Alan Hofmann, Peter Fickert
-
Publication number: 20150032201Abstract: The invention relates to a composite material that comprises at least one magnesium component, whereby the magnesium component consists of pure magnesium or a magnesium-calcium alloy or a magnesium-calcium-X alloy, whereby X is another biodegradable element. The composite material also contains at least one organic anti-infective agent having a solubility in water at room temperature of less than 10 grams per liter.Type: ApplicationFiled: July 22, 2014Publication date: January 29, 2015Applicants: MEDIZINISCHE UNIVERSITÄT GRAZ, HERAEUS MEDICAL GMBHInventors: KLAUS-DIETER KÜHN, ANNELIE WEINBERG, PETER UGGOWITZER, SEBASTIAN VOGT, JÖRG LÖFFLER
-
Publication number: 20140228449Abstract: The present invention relates to a novel polymeric material with enhanced hydrophilicity for medical use comprising a biocompatible polyester material selected from the group consisting of poly(hydroxyalkanoate)s, poly(lactic acid)s, poly(glycolic acid)s, poly(caprolactone)s and copolymers and blends thereof, wherein the biocompatible polyester material is crosslinked with a functionalized poly(alkylene oxide) having at least two functional groups independently selected from the group consisting of azido-formate and alkanoyl azide. The novel polymeric material with enhanced hydrophilicity is useful as a biocompatible material in a variety of medical applications, including medical implants, bioresorbable implants, tissue engineering, and controlled release.Type: ApplicationFiled: June 20, 2012Publication date: August 14, 2014Applicant: Technische Universitat GrazInventors: Frank Wiesbrock, Clemens Ebner, Franz Stelzer, Annelie-Martina Weinberg, Klaus-Dieter Kühn
-
Publication number: 20140213746Abstract: The present invention relates to pre-catalysts for olefin metathesis and composition involving these pre-catalysts.Type: ApplicationFiled: September 3, 2012Publication date: July 31, 2014Applicant: Technische Universität GrazInventors: Christian Slugovc, Julia Wappel
-
Publication number: 20140206738Abstract: A compound of formula (I) as defined herein is useful in the treatment and prevention of a disorder such as cachexia, stroke, atherosclerosis, coronary artery disease, and diabetes and pharmaceutical compositions of the same. Also, a method of screening for lipase inhibitors using a compound of formula (I) and determining its lipase inhibitory activity. The method includes in vitro assays of compounds using ATGL and/or HSL, and cellular assays wherein inhibition is followed by observing indicators of efficacy. Also, methods for treatment or prevention of a condition involving cachexia, stroke, artherosclerosis, coronary artery disease, diabetes, preferably diabetes type II by administering a pharmaceutical composition comprising an agent which is able to inhibit ATGL. Also contemplated herein, are compositions comprising one or more ATGL-inhibiting agents optionally in combination with one or more lipase inhibitors or inhibitors of inflammatory cytokines.Type: ApplicationFiled: January 23, 2014Publication date: July 24, 2014Applicants: Karl-Franzens-Universität Graz, Technische Universität GrazInventors: Martina SCHWEIGER, Matthias ROMAUCH, Robert ZIMMERMANN, Nicole MAYER, Rolf BREINBAUER
-
Patent number: 8767993Abstract: A sensor system is located in an environment composed of a first medium, where waves propagate with a first phase velocity, the sensor system including at least one main enclosure and a sensor array with at least two sensors, said sensor array being arranged inside the main enclosure, wherein the space inside the main enclosure between the sensor array and the inner surface of the main enclosure is filled with a second medium, in which waves propagate with a second phase velocity, the second phase velocity being different from the first velocity.Type: GrantFiled: November 10, 2008Date of Patent: July 1, 2014Assignee: Technische Universitat GrazInventors: Gernot Kubin, Marián Képesi, Michael Stark
-
Publication number: 20140024702Abstract: The invention relates to the gene therapeutic treatment of cancer using co-expressed nucleic acids encoding US28 and a G-protein. e.g. GNA-13, or functional fragments thereof, or using nucleic acids encoding fusion polypeptides of US28 and a G-protein or functional fragments thereof. The pharmaceutical compositions according to the invention are used in the treatment of cancer patients to induce apoptosis in tumor cells.Type: ApplicationFiled: December 9, 2011Publication date: January 23, 2014Applicant: Medizinische Universitat GrazInventors: Helmut Schaider, Shripad Joshi
-
Publication number: 20130331440Abstract: The present invention relates to compositions comprising an agent, like a polynucleotide, which induces or upregulates expression of UCP1 for use in treating or preventing a disorder of the energy homeostasis, overweight, adiposity, obesity, metabolic syndrome or related diseases or disorders in a subject. The present invention also relates to a method of treating or preventing a disorder of the energy homeostasis, overweight, adiposity, obesity, metabolic syndrome or related diseases or disorders in a subject comprising administrating a composition comprising a polynucleotide which induces or upregulates expression of UCP1.Type: ApplicationFiled: May 6, 2011Publication date: December 12, 2013Applicant: TECHNISCHE UNIVERSITAT GRAZInventors: Marcel Scheideler, Michael Karbiener, Ez-Zoubir Amri, Gérard Ailhaud, Christian Dani
-
Patent number: 8497085Abstract: Described herein is a method for detecting a wound infection comprising the steps of: contacting a sample obtained from a wound with at least two substrates for at least two enzymes selected from the group consisting of lysozyme, elastase, cathepsin G and myeloperoxidase, and detecting a wound infection when a conversion of the at least two substrates with said at least two enzymes are determined.Type: GrantFiled: November 17, 2011Date of Patent: July 30, 2013Assignees: Technische Universitat Graz, Forschungsholding Tu Graz GmbH, Medicinische Universitat GrazInventors: Georg Gübitz, Eva Wehrschütz-Sigl, Andrea Hasmann, Barbara Binder, Michael Burnett, Michael Schintler
-
Publication number: 20130151245Abstract: The invention relates to a method for establishing fundamental frequency curves of a plurality of signal sources from a single-channel audio recording of a mix signal, said method including the following steps: a) establishing the spectrogram properties of the pitch states of individual signal sources with use of training data; b) establishing the probabilities of the fundamental frequency combinations of the signal sources contained in the mix signal by a combination of the properties established in a) by means of an interaction model; and c) tracking the fundamental frequency curves of the individual signal sources.Type: ApplicationFiled: February 22, 2011Publication date: June 13, 2013Applicant: TECHNISCHE UNIVERSITAT GRAZInventors: Michael Stark, Michael Wohlmayr, Franz Pernkopf
-
Publication number: 20130126725Abstract: A method for analysis of analytes in a sample and to the use of such a method and a method for monitoring progress, or treatment of a disease such as fat-related disease. These analysis methods include the steps of providing the sample, measuring of values of analytes in the sample, calculating of values based on the measured values, identifying and optionally visualizing analytes can particularly be used for monitoring quantitative changes of analytes and for monitoring progress or treatment of a disease such as a fat-related disease.Type: ApplicationFiled: July 26, 2011Publication date: May 23, 2013Applicant: TECHNISCHE UNIVERSITÄT GRAZInventors: Jurgen Hartler, Gerhard Thallinger
-
Publication number: 20130113896Abstract: Method for compensating illumination deficiencies in microscopic “shape from focus (SFF)”, wherein firstly the reflectance of the scene is estimated by way of a projector-camera system and then microscopic “shape from focus (SFF)” is applied to a stack of reflectance maps rather than to the original image data.Type: ApplicationFiled: July 26, 2011Publication date: May 9, 2013Applicants: TECHNISCHE UNIVERSITAT GRAZ, ALICONA IMAGING GMBHInventors: Manfred Prantl, Stefan Scherer, Martin Lenz, Matthias Ruther, Horst Bischof